Abstract:The purpose of this study was to investigate the antitumor effects and drug interactions of the proteasome inhibitor Bortezomib against high-risk myelodysplastic syndrome (MDS) cells in vitro and in vivo. The high-risk MDS-derived MUTZ-1 cell line and bone marrow mononuclear cells from primary high-risk MDS patients were used to examine antitumor activity and drug interactions for Bortezomib. Apoptotic proteins, including caspase and Bcl-2 family members, as well as the protein FLIP, were studied. Phosphoinositide 3-kinase (PI3K)/Akt and MAPK signaling pathways were also examined. The PI3K inhibitor LY294002 was used to examine the involvement of the PI3K/Akt signaling pathway in the induction of apoptosis. Cytarabine (AraC) and daunorubicin (DNR) were used to test for synergistic effects between Bortezomib and chemotherapeutic agents. SCID mice xenografted with MUTZ-1 cells were used for in vivo study. We found that Bortezomib could induce growth arrest and apoptosis in high-risk MDS cells in vitro and in vivo. The mechanisms were related to decreased activation of the PI3K/Akt survival signaling pathway, but not the MAPK pathway, and involved inhibition of the NF-κB activity and downregulation of the Bcl-2/Bax and FLIPL/FLIPS ratios, triggering the activation of caspase cascades. This phenomenon was inhibited by the PI3K inhibitor LY294002. Bortezomib also acted synergistically with the chemotherapeutic agents AraC and DNR, which are associated with the inhibition of NF-κB activity. Our results demonstrate that Bortezomib can induce growth arrest and apoptosis of high-risk MDS cells and had a synergistic effect with two chemotherapeutic agents. Our findings provide new insights for the treatment of high-risk MDS, using either Bortezomib alone, or in combination with conventional antineoplastic agents.

Plasma Enhance Drug Sensitivity to Bortezomib by Inhibition of Cyp1a1 in Myeloma Cells

The Effects of Cold Atmospheric Plasma on Cell Adhesion, Differentiation, Migration, Apoptosis and Drug Sensitivity of Multiple Myeloma.

Synergistic Cytotoxicity Between Cold Atmospheric Plasma and Pyrazolopyrimidinones Against Glioblastoma Cells

Cold Atmospheric Plasma As a Potential Tool for Multiple Myeloma Treatment

Down-Regulation of CD9 by Methylation Decreased Bortezomib Sensitivity in Multiple Myeloma

Curcumin Enhances Bortezomib Treatment of Myeloma by Inhibiting Heat Shock Protein 90 Expression

Blockade of HSP70 by VER-155008 Synergistically Enhances Bortezomib-Induced Cytotoxicity in Multiple Myeloma

Enhanced Pyrazolopyrimidinones Cytotoxicity Against Glioblastoma Cells Activated by ROS-Generating Cold Atmospheric Plasma.

Alteration of Metabolite Profiling by Cold Atmospheric Plasma Treatment in Human Myeloma Cells

Blockade of PLD1 Potentiates the Antitumor Effects of Bortezomib in Multiple Myeloma Cells by Inhibiting the Mtor/nf-Κb Signal Pathway

Bortezomib Potentiates Antitumor Activity of Mitoxantrone Through Dampening Wnt/β-catenin Signal Pathway in Prostate Cancer Cells

Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Restoration of Sensitivity in Chemo — Resistant Glioma Cells by Cold Atmospheric Plasma

Antitumor Activity and Drug Interactions of Proteasome Inhibitor Bortezomib in Human High-Risk Myelodysplastic Syndrome Cells.

Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy

Combined Anticancer Effect of Treatment with Cold Atmospheric Plasma and Thymidine

Trident cold atmospheric plasma blocks three cancer survival pathways to overcome therapy resistance

Biomimetic Platelet Nanoparticles Encapsulated with Proteasome Inhibitor Bortezomib for Multiple Myeloma Treatment

Blockade Of Deubiquitinase Usp7 Overcomes Bortezomib Resistance By Suppressing Nf-Kappa B Signaling Pathway In Multiple Myeloma

[Bortezomib-Based Chemotherapy for Patients with Multiple Myeloma: a Single Center Experience].